JP2010540602A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540602A5 JP2010540602A5 JP2010527496A JP2010527496A JP2010540602A5 JP 2010540602 A5 JP2010540602 A5 JP 2010540602A5 JP 2010527496 A JP2010527496 A JP 2010527496A JP 2010527496 A JP2010527496 A JP 2010527496A JP 2010540602 A5 JP2010540602 A5 JP 2010540602A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- groups
- compound
- halogen atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000005843 halogen group Chemical group 0.000 claims description 42
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 31
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 10
- 125000004043 oxo group Chemical group O=* 0.000 claims description 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical group C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000003367 polycyclic group Chemical group 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- -1 cyano, amino Chemical group 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 24
- 230000002265 prevention Effects 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- OUOGAMDCVPYBRH-UHFFFAOYSA-N 4-[6-(1,3-difluoropropan-2-yloxy)-2,4-dioxoquinazolin-1-yl]piperidine-1-carbaldehyde Chemical compound O=C1NC(=O)C2=CC(OC(CF)CF)=CC=C2N1C1CCN(C=O)CC1 OUOGAMDCVPYBRH-UHFFFAOYSA-N 0.000 claims 1
- TXEZVKHORRCRLJ-UHFFFAOYSA-N 4-[6-(2,2-difluoroethoxy)-2,4-dioxoquinazolin-1-yl]piperidine-1-carbaldehyde Chemical compound O=C1NC(=O)C2=CC(OCC(F)F)=CC=C2N1C1CCN(C=O)CC1 TXEZVKHORRCRLJ-UHFFFAOYSA-N 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 238000006751 Mitsunobu reaction Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000000495 immunoinflammatory effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 0 C*CC(CN(CCC1C)C(*)=O)*(C)C1N(c(c(C(N1)=O)c2)ccc2O*)C1=O Chemical compound C*CC(CN(CCC1C)C(*)=O)*(C)C1N(c(c(C(N1)=O)c2)ccc2O*)C1=O 0.000 description 1
- 125000005124 aminocycloalkyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0706931 | 2007-10-03 | ||
| FR0706931A FR2921926B1 (fr) | 2007-10-03 | 2007-10-03 | Derives de quinazolinedione,leur preparation et leurs applications therapeutiques. |
| PCT/FR2008/001384 WO2009077680A1 (fr) | 2007-10-03 | 2008-10-03 | Dérivés de quinazolinedione, leur préparation et leurs applications thérapeutiques |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010540602A JP2010540602A (ja) | 2010-12-24 |
| JP2010540602A5 true JP2010540602A5 (enExample) | 2011-09-29 |
| JP5411143B2 JP5411143B2 (ja) | 2014-02-12 |
Family
ID=39470387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010527496A Expired - Fee Related JP5411143B2 (ja) | 2007-10-03 | 2008-10-03 | キナゾリンジオン誘導体、その調製およびその治療上の使用 |
Country Status (40)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8107260B2 (en) * | 2007-11-15 | 2012-01-31 | Illinois Tool Works Inc. | EMI shielding and environmental seal device |
| FR2943673B1 (fr) * | 2009-03-27 | 2013-03-29 | Sanofi Aventis | Applications therapeutiques de derives de quinazolinedione |
| FR2944206B1 (fr) * | 2009-04-09 | 2012-12-28 | Sanofi Aventis | Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione |
| FR2944282B1 (fr) * | 2009-04-09 | 2013-05-03 | Sanofi Aventis | Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques |
| KR101116234B1 (ko) * | 2009-10-29 | 2014-03-06 | (주)퓨쳐켐 | (3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물 |
| EP2576536B1 (en) * | 2010-06-01 | 2016-09-14 | The University of Queensland | Haematopoietic-prostaglandin d2 synthase inhibitors |
| KR20150003849A (ko) * | 2012-04-24 | 2015-01-09 | 추가이 세이야쿠 가부시키가이샤 | 퀴나졸린디온 유도체 |
| BR112014026266A2 (pt) | 2012-04-24 | 2017-06-27 | Chugai Pharmaceutical Co Ltd | derivado de quinazolidinadiona |
| EP2854780B1 (en) | 2012-06-05 | 2017-08-30 | University Of Kansas | Inhibitors of respiratory syncytial virus |
| WO2015003879A1 (en) * | 2013-07-08 | 2015-01-15 | Syngenta Participations Ag | Microbiocidal heterobicylic derivatives |
| CN105829285A (zh) | 2013-10-23 | 2016-08-03 | 中外制药株式会社 | 喹唑啉酮和异喹啉酮衍生物 |
| CZ2015601A3 (cs) * | 2015-09-02 | 2017-03-15 | Zentiva, K.S. | Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty |
| CN107267455A (zh) * | 2017-08-23 | 2017-10-20 | 安徽惠恩生物科技股份有限公司 | 一种嵌合抗原受体nk细胞的制备方法 |
| GB201918416D0 (en) | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency |
| EP4572765A1 (en) | 2022-08-18 | 2025-06-25 | Mitodicure GmbH | Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
| US12258345B1 (en) | 2023-12-12 | 2025-03-25 | King Faisal University | Pyrrolo[3,2-c]isoquinoline-2,3-dione compounds as CK2 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5264437A (en) * | 1992-03-20 | 1993-11-23 | Syntex (U.S.A.) Inc. | Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones |
| CA2218548A1 (en) * | 1995-05-19 | 1996-11-21 | Chiroscience Limited | Xanthines and their therapeutic use |
| JP2002308774A (ja) * | 2001-04-12 | 2002-10-23 | Nippon Zoki Pharmaceut Co Ltd | Ｉｖ型ホスホジエステラーゼ選択的阻害剤 |
| WO2002088079A2 (en) * | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| WO2006092692A1 (en) | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
| BRPI0607402A2 (pt) | 2005-03-01 | 2009-09-01 | Pfizer Ltd | uso de inibidores de pde7 para o tratamento de dor neuropática |
| WO2007067946A2 (en) | 2005-12-07 | 2007-06-14 | The Regents Of The University Of California | Diagnosis and treatment of chronic lymphocytic leukemia (cll) |
-
2007
- 2007-10-03 FR FR0706931A patent/FR2921926B1/fr not_active Expired - Fee Related
-
2008
- 2008-10-01 AR ARP080104293A patent/AR070655A1/es unknown
- 2008-10-01 PE PE2008001713A patent/PE20090960A1/es not_active Application Discontinuation
- 2008-10-02 PA PA20088797701A patent/PA8797701A1/es unknown
- 2008-10-02 CL CL2008002946A patent/CL2008002946A1/es unknown
- 2008-10-02 TW TW097137995A patent/TWI421076B/zh not_active IP Right Cessation
- 2008-10-03 JP JP2010527496A patent/JP5411143B2/ja not_active Expired - Fee Related
- 2008-10-03 BR BRPI0818690 patent/BRPI0818690A2/pt not_active IP Right Cessation
- 2008-10-03 AU AU2008337382A patent/AU2008337382B2/en not_active Ceased
- 2008-10-03 UY UY31376A patent/UY31376A1/es not_active Application Discontinuation
- 2008-10-03 KR KR1020107009640A patent/KR20100082345A/ko not_active Ceased
- 2008-10-03 HR HRP20160359TT patent/HRP20160359T1/hr unknown
- 2008-10-03 DK DK08862034.9T patent/DK2205593T3/en active
- 2008-10-03 MY MYPI2010001434A patent/MY153763A/en unknown
- 2008-10-03 NZ NZ584430A patent/NZ584430A/en not_active IP Right Cessation
- 2008-10-03 WO PCT/FR2008/001384 patent/WO2009077680A1/fr not_active Ceased
- 2008-10-03 PL PL08862034.9T patent/PL2205593T3/pl unknown
- 2008-10-03 ES ES08862034T patent/ES2567567T3/es active Active
- 2008-10-03 UA UAA201005204A patent/UA99485C2/ru unknown
- 2008-10-03 CN CN200880114378.7A patent/CN101842368B/zh not_active Expired - Fee Related
- 2008-10-03 EP EP08862034.9A patent/EP2205593B1/fr active Active
- 2008-10-03 EA EA201070424A patent/EA018766B1/ru not_active IP Right Cessation
- 2008-10-03 MX MX2010003495A patent/MX2010003495A/es active IP Right Grant
- 2008-10-03 SI SI200831596A patent/SI2205593T1/sl unknown
- 2008-10-03 HU HUE08862034A patent/HUE028770T2/en unknown
- 2008-10-03 CA CA2701150A patent/CA2701150C/fr not_active Expired - Fee Related
-
2010
- 2010-03-19 NI NI201000039A patent/NI201000039A/es unknown
- 2010-03-22 CR CR11327A patent/CR11327A/es unknown
- 2010-03-22 TN TNP2010000130A patent/TN2010000130A1/fr unknown
- 2010-03-22 DO DO2010000089A patent/DOP2010000089A/es unknown
- 2010-03-25 SV SV2010003514A patent/SV2010003514A/es not_active Application Discontinuation
- 2010-03-25 GT GT201000069A patent/GT201000069A/es unknown
- 2010-03-26 HN HN2010000572A patent/HN2010000572A/es unknown
- 2010-03-26 CO CO10036551A patent/CO6270227A2/es active IP Right Grant
- 2010-03-28 IL IL204814A patent/IL204814A0/en unknown
- 2010-03-29 EC EC2010010058A patent/ECSP10010058A/es unknown
- 2010-03-31 ZA ZA2010/02307A patent/ZA201002307B/en unknown
- 2010-04-05 US US12/754,163 patent/US8242126B2/en not_active Expired - Fee Related
- 2010-05-03 MA MA32815A patent/MA31832B1/fr unknown
-
2016
- 2016-04-12 CY CY20161100303T patent/CY1117461T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010540602A5 (enExample) | ||
| ES3043457T3 (en) | Rip1 inhibitory compounds and methods for making and using the same | |
| TWI723158B (zh) | 芳族磺醯胺衍生物 | |
| CN102239164B (zh) | 2h-色烯化合物及其衍生物 | |
| KR102229608B1 (ko) | Ror 감마 조절제로서의 신규한 화합물 | |
| JP2016514719A5 (enExample) | ||
| JP2020012001A (ja) | Ｔａｍ ｒｔｋインヒビターとしてのキノリン誘導体 | |
| EP3209665B1 (en) | Substituted pyrrolotriazine amine compounds as pi3k inhibitors | |
| JP2010539095A5 (enExample) | ||
| JP2016534146A5 (enExample) | ||
| JP2017510643A5 (enExample) | ||
| HUE031400T2 (en) | Condensed bicyclic sulfamoyl derivatives and their use as medicaments for the treatment of hepatitis B | |
| IL228103A (en) | Amino-quinolines as kinase inhibitors | |
| JP2017510642A5 (enExample) | ||
| JP6257787B2 (ja) | Ｅｇｆｒ−ｔ７９０ｍキナーゼ阻害剤として置換されたピリミジニウム類化合物 | |
| CA2988637A1 (en) | Aromatic sulfonamide derivatives | |
| JP2018509438A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2017531000A5 (enExample) | ||
| TW200535135A (en) | N-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl]sulfonamide derivatives, preparation and therapeutic application thereof | |
| BR112014009084B1 (pt) | Polimorfos cristalinos de arry-380 | |
| JPWO2017086430A1 (ja) | Ｎａｓｈの治療又は予防のための医薬組成物 | |
| CA3079469A1 (en) | Aromatic sulfonamide derivatives for the treatment of ischemic stroke | |
| JP2007217282A (ja) | 置換ピリミジン誘導体 | |
| JP2019526593A5 (enExample) |